Welcome New Faculty & Board Member
The UCLA Institute of Urologic Oncology (IUO) is pleased to announce the addition of a new Board of Directors Member, Dr. Johannes Czernin, along with the successful recruitment of three new faculty to UCLA – Dr. Paul Boutros, Dr. Brian Shuch and Dr. Huihui Ye. These compliment the IUO’s three other new UCLA faculty additions – Dr. Jeremy Calais, Dr. John Shen and Dr. David Ulmert. Learn more about these outstanding new IUO members >
The OLYMPUS Study - Optimized Delivery of Mitomycin for Primary UTUC Study
The purpose of this research study is to test the ability of UroGen’s MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. View Clinical Trial >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
UCLA researchers develop mechanism for characterizing function of rare tumor cells
UCLA researchers, including IUO's Dr. Matthew Rettig, have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive the disease of cancer. These findings could lead to more personalized treatments for people with cancer.